A PALB2 mutation associated with high risk of breast cancer

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Southey, Melissa C ^a,g   Teo, Zhi L ^a   Dowty, James G ^a   Odefrey, Fabrice A ^a   Park, Daniel J ^a   Tischkowitz, Marc ^b,c   Sabbaghian, Nelly ^b   Apicella, Carmel ^a   Byrnes, Graham B ^d   Winship, Ingrid ^a   Baglietto, Laura ^a,e   Giles, Graham G ^a,e   Goldgar, David E ^f   Foulkes, William D ^b,c   Hopper, John L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ONCOPROTEIN; PROTEIN P53; PROTEIN PALB2; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HAZARD RATIO; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NEW ZEALAND; NUCLEOTIDE SEQUENCE; ONSET AGE; PEDIGREE ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; RISK ASSESSMENT; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; RISK;

ADULT; AGE OF ONSET; AUSTRALIA; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; RISK; TUMOR SUPPRESSOR PROTEINS;

EID: 78650389153     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2796     Document Type: Article

References (42)

1. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008, 40:17-22. 10.1038/ng.2007.53, 18163131.
2. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Breast Cancer Susceptibility Collaboration (UK) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006, 38:873-875. 10.1038/ng1837, 16832357, Breast Cancer Susceptibility Collaboration (UK).
3. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Breast Cancer Susceptibility Collaboration (UK) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241. 10.1038/ng1902, 17033622, Breast Cancer Susceptibility Collaboration (UK).
4. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. Breast Cancer Susceptibility Collaboration (UK) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 2871593, 17200668, Breast Cancer Susceptibility Collaboration (UK).
5. Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?. Breast Cancer Res 2008, 10:208. 10.1186/bcr2099, 2481495, 18557994.
6. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the Breast Cancer Family Registry. Hum Mutat 2006, 27:1122-1128. 10.1002/humu.20415, 16958054.
7. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM, Whiteman DC, Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G. Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab) Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009, 85:427-446. 10.1016/j.ajhg.2009.08.018, 2756555, 19781682, Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab).
8. Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 2008, 14:4667-4671. 10.1158/1078-0432.CCR-08-0210, 18628482.
9. McCredie MR, Dite GS, Giles GG, Hopper JL. Breast cancer in Australian women under the age of 40. Cancer Causes Control 1998, 9:189-198. 10.1023/A:1008886328352, 9578296.
10. Hopper JL, Giles GG, McCredie MR, Boyle P. Background rational and protocol for a case-control-family study of breast cancer. Breast 1994, 3:79-86.
11. Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Cooperative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr 1999, 26:95-100.
12. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D, . Breast Cancer Family Registry The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004, 6:R375-R389. 10.1186/bcr801, 468645, 15217505, Breast Cancer Family Registry.
13. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003, 95:448-457. 10.1093/jnci/95.6.448, 12644538.
14. Smith LD, Tesoriero AA, Ramus SJ, Dite G, Royce SG, Giles GG, McCredie MR, Hopper JL, Southey MC. BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. Eur J Cancer 2007, 43:823-827. 10.1016/j.ejca.2007.01.011, 2222980, 17317153.
15. Southey MC, Tesoriero AA, Andersen CR, Jennings KM, Brown SM, Dite GS, Jenkins MA, Osborne RH, Maskiell JA, Porter L, Giles GG, McCredie MR, Hopper JL, Venter DJ. BRCA1 mutations and other sequence variants in a population based sample of Australian women with breast cancer. Br J Cancer 1999, 79:34-39. 10.1038/sj.bjc.6690008, 2362179, 10408690.
16. Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS, . Cooperative Family Registry for Breast Cancer studies Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 2002, 20:65-73. 10.1002/humu.10097, 12112659, Cooperative Family Registry for Breast Cancer studies.
17. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dörk T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002, 94:205-215.
18. Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey MC, Venter DJ, Hopper JL. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 2003, 5:R206-R216. 10.1186/bcr644, 314405, 14580256.
19. Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, Senie RT, Terry MB, . Breast Cancer Family Registry BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat 2009, 116:379-386. 10.1007/s10549-008-0153-8, 2775077, 18704680, Breast Cancer Family Registry.
20. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 2010, 70:4795-4800. 10.1158/0008-5472.CAN-09-0851, 20501846.
21. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G, . Kathleen Cuningham Consortium for Research in Familial Breast Cancer Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006, 8:R12. 10.1186/bcr1377, 1413975, 16507150, Kathleen Cuningham Consortium for Research in Familial Breast Cancer.
22. Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 2008, 68:675-678. 10.1002/pros.20729, 2683627, 18288683.
23. Nguyen-Dumont T, Calvez-Kelm FL, Forey N, McKay-Chopin S, Garritano S, Gioia-Patricola L, De Silva D, Weigel R, Sangrajrang S, Lesueur F, Tavtigian SV, . Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) Description and validation of high-throughput simultaneous genotyping and mutation scanning by high-resolution melting curve analysis. Hum Mutat 2009, 30:884-890. 10.1002/humu.20949, 19347964, Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
24. Jiménez Ide J, Esteban Cardeñosa E, Palanca Suela S, Barragán González E, Bolufer Gilabert P, . on behalf of the Group of Cancer Genetic Counselling Program of Valencia Community Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers. Clin Biochem 2009, 42:1572-1576. on behalf of the Group of Cancer Genetic Counselling Program of Valencia Community.
25. Orlando C, Pinzani P, Pazzagli M. Developments in quantitative PCR. Clin Chem Lab Med 1998, 36:255-269. 10.1515/CCLM.1998.045, 9676381.
26. Ratnasinghe LD, Abnet C, Qiao YL, Modali R, Stolzenberg-Solomon R, Dong ZW, Dawsey SM, Mark SD, Taylor PR. Polymorphisms of XRCC1 and risk of esophageal and gastric cardia cancer. Cancer Lett 2004, 216:157-164. 10.1016/j.canlet.2004.03.012, 15533591.
27. Jenkins MA, Baglietto L, Dowty JG, Van Vliet CM, Smith L, Mead LJ, Macrae FA, St John DJ, Jass JR, Giles GG, Hopper JL, Southey MC. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006, 4:489-498. 10.1016/j.cgh.2006.01.002, 16616355.
28. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 1998, 5:471-472.
29. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in additional to BRCA1 and BRCA2 in a population based study. Genet Epidemiol 2001, 21:1-18. 10.1002/gepi.1014, 11443730.
30. Cannings C, Thompson EA, Skolnick MH. Probability functions on complex pedigrees. Adv Appl Prob 1978, 10:26-61.
31. Lange K. Mathematical and Statistical Methods for Genetic Analysis 2002, New York: Springer, 2.
32. Australian Institute of Health and Welfare and National Breast Cancer Centre Breast cancer in Australia: an overview. 2006, Australian Institute of Health and Welfare and National Breast Cancer Centre., http://www.aihw.gov.au/publications/can/bca06/bca06.pdf
33. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002, 86:76-83. 10.1038/sj.bjc.6600008, 2746531, 11857015.
34. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130. 10.1086/375033, 1180265, 12677558.
35. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319. 10.1038/nature05609, 17287723.
36. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau F, Narod SA. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 2007, 9:R83. 10.1186/bcr1828, 2246183, 18053174.
37. Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D. A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer 2010, 9:181-185. 10.1007/s10689-009-9295-z, 19763884.
38. García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramóny Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J. Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 2009, 113:545-551.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958, 53:457-481.
40. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008, 98:1457-1466. 10.1038/sj.bjc.6604305, 2361716, 18349832.
41. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009, 115:2222-2233. 10.1002/cncr.24200, 2771545, 19241424.
42. Hopper JL. Genetic epidemiology of female breast cancer. Semin Cancer Biol 2001, 11:367-374. 10.1006/scbi.2001.0392, 11562179.